SRTD Biotech
Germany · Biotech · Healthtech
SRTD Biotech develops RNA therapies designed to activate selectively inside diseased cells.
Product
SRTD Biotech develops selectively expressed RNA therapeutics. Its constructs are designed to remain inactive until they detect an RNA marker associated with disease inside a target cell, then express a therapeutic payload.
The Jülich company combines RNA design and marker discovery with lipid nanoparticle delivery. Its preclinical programmes address cancer, autoimmune conditions and severe liver diseases.
Funding history
2 rounds · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed | €31.5M | Boehringer Ingelheim Venture Fund — LeadMérieux Innovation 2 — LeadNRW.Venture EU Tech&Scale — LeadAnobis Asset — ParticipantEli Lilly Ventures — ParticipantHigh-Tech Gründerfonds — Participant | |
| Seed | Undisclosed | High-Tech Gründerfonds — Lead |
Investors
Boehringer Ingelheim Venture FundLed SeedMérieux Innovation 2Led SeedNRW.Venture EU Tech&ScaleLed SeedAnobis AssetJoined SeedEli Lilly VenturesJoined SeedHigh-Tech GründerfondsJoined Seed · Led SeedCoverage
Nov 9, 2026SRTD Biotech · SeedNov 14, 2024SRTD Biotech · SeedSimilar companies
BMBoston Medical SciencesBoston Medical Sciences develops AI-assisted colorectal cancer screening technology.¥5.6B · Series B
SSSunlit SeedlingsSunlit Seedlings measures biodiversity and microbial activity to help organisations assess and redesign ecosystems.Undisclosed · Corporate investment
BiomatterBiomatter designs custom enzymes for pharmaceutical, diagnostic, agricultural and industrial applications.$18M · Series A